截至2025年11月14日收盘，心脉医疗(688016)报收于102.25元，上涨0.25%，换手率1.65%，成交量2.04 万手，成交额2.12亿元。 当日关注点 交易信息汇总资金流向 11月14日主力资金净流出462.28万元，占总成交额2.18%；游资资金净流入1128.65万元，占总成交额 5.33%；散户资金净流出666.37万元，占总成交额3.15%。 心脉医疗：2025年第一次临时股东大会决议公告 上海微创心脉医疗科技（集团）股份有限公司于2025年11月14日召开2025年第一次临时股东大会，审议 通过了关于取消监事会并修订《公司章程》及办理工商变更登记的议案、关于修订及新增公司部分管理 制度的议案、关于购买董事及高级管理人员责任险的议案。会议由董事会召集，董事长Jonathan Chen主 持，采用现场与网络投票相结合方式召开，表决结果合法有效。其中，取消监事会为特别决议议案，已 获出席股东所持表决权三分之二以上通过；购买董监高责任险议案对中小投资者单独计票。 心脉医疗：关于选举第三届董事会职工代表董事的公告 上海微创心脉医疗科技（集团）股份有限公司于2025年11月14日召开职工代表大会 ...

截至2025年11月14日收盘，迈瑞医疗(300760)报收于207.7元，下跌0.24%，换手率0.43%，成交量5.17万 手，成交额10.8亿元。 当日关注点 交易信息汇总资金流向 11月14日主力资金净流出646.51万元；游资资金净流入483.43万元；散户资金净流入163.08万元。 大宗交易 投资者： 联影医疗去年的研发投入占收入比为17%，国外如直觉外科为13.5%，世界排名第十的波士顿 科学为11%，其它友商基本都在10%以上，公司做为医疗高科技领域的追赶者，想要5年内冲进世界前 十，困难重重，不加大研发投入是根本不可能的，目前10%左右的研发投入是否太少了，公司是有进一 步加大研发投入的计划？ 董秘： 您好，谢谢关注。迈瑞是全球领先、创新驱动的世界级医疗器械企业及医疗数智化引领者。我 们始终坚持以研发创新为核心驱动力，持续加大投入，依托深厚的技术实力以及对临床需求的深刻洞 察，不断引领并推出契合市场的前沿产品。公司坚持研发高投入，即使在营收规模快速增长的情况下， 依然坚持将每年营收的约10%投入研发，研发投入比例和规模均在医疗器械企业中处于领先地位。截至 2025年三季度末，公司自2018 ...

复锐医疗 20251114 摘要 福瑞医疗预计 2025 年全年业绩将显著增长，完全弥补上半年 1.9%的 下降，并预计 2026 年销售额将实现双位数增长，主要受益于达西菲 （Daxify）的发布。 达西菲（Daxify）商业化稳步推进，预计年底前完成中检院检验并全面 铺货上市，首年销售目标为 1 亿人民币，未来 3-5 年累计销售额目标为 10-20 亿人民币，占据肉毒市场约 1/3 份额。 普发乐（Profile）市场表现超出预期，在泰国发售后前九个月已实现上 千万美元销售额，预计全年销售额可达 3,000 万美元，并计划 2027 年 在中国大陆市场正式销售，预期中国市场销售额有望过亿。 能量源业务持续增长，第三季度新订单实现双位数增长，新产品如胎提 升设备、Harmony 和 Suprano 销量良好，并积极布局能量设备国产化， 预计明年上半年首台国产化设备落地。 福瑞医疗计划调整业务结构，将能量设备与注射填充类产品占比从 80%/10%调整为 60%/40%，以优化公司业务结构并提高估值倍数， 目前正拆分两条业务线以清晰展示各自利润率。 Q&A 福瑞医疗在 2025 年第三季度的业务表现如何？ 2 ...

Group 1 - Stanford University and Elsevier published the 2025 "Top 2% Global Scientists" list, recognizing the top 2% of scholars from nearly 7 million researchers worldwide [1] - Professor He Xiaoshun, Director of the Organ Transplant Center at Sun Yat-sen University First Affiliated Hospital, was honored on this list and is also the founder and chief scientist of Singularity Medical Technology [2] Group 2 - Professor He Xiaoshun is a pioneer in organ medicine, having performed the world's first non-ischemic liver transplant in 2017 and introduced the concept of "organ medicine" in 2019 [3] - The "Domino-Extracorporeal Liver Support Therapy" developed by his team provides new hope for critically ill patients who cannot undergo transplantation [3] - The "extracorporeal liver" technology allows for the maintenance of non-transplantable but functional livers, providing essential liver function support to patients in need [3] Group 3 - Singularity Medical, established in May 2020, focuses on organ medicine research and development, with a pipeline covering organ transplantation, donation, isolation treatment, and new drug development [4] - The company has achieved significant milestones, including the world's first vascular intervention for liver cancer isolation treatment and the revival of a pig brain after 50 minutes of death [4] - The company has a strong R&D team, with 51% of its workforce dedicated to research, and has filed 61 patents, with 44 granted [4] Group 4 - Singularity Medical's first innovative medical device, the "Liver Perfusion System," has entered the special review process by the National Medical Products Administration, with full case enrollment expected by October 2025 and registration anticipated by 2027 [4] - Another core product, the "Donor Perfusion System," received approval for special review in June 2025, with efforts underway to expedite clinical trials [4]

Core Viewpoint - Domestic influenza activity is showing a significant upward trend, with an increase in reported ILI% and positive rates of influenza virus testing compared to the previous week [1] Group 1: Influenza Activity - Both northern and southern regions of China are experiencing a rise in influenza-like illness (ILI) cases and positive influenza virus test rates [1] - Influenza activity in countries like Japan and the UK remains high, surpassing levels seen in the same period in previous years [1] Group 2: Dominant Strains and Vaccination - The dominant strain in China is the A(H3N2) subtype, prompting updates to the influenza vaccine composition in the new vaccination guidelines [1] - The updated vaccination guidelines provide specific recommendations for vulnerable groups, including pregnant women and individuals allergic to eggs, along with the optimal vaccination timing [1] Group 3: Treatment and Recommendations - Vaccination is highlighted as the most effective method for preventing influenza and reducing severe cases [1] - The influenza diagnosis and treatment protocols are well-established, utilizing antigen and nucleic acid testing for early diagnosis, with treatment options including symptomatic care and antiviral therapy [1] - There is a recommendation to pay attention to influenza vaccines, respiratory medications, and related diagnostic products [1]

Group 1 - The report highlights that the Beijing Stock Exchange (BSE) has evolved from a "testing ground" to a main battleground for specialized and innovative enterprises, with 282 listed companies and a total market capitalization of 900.835 billion yuan as of November 14, 2025 [2][12][14] - Among the listed companies, 254 are classified as specialized and innovative "little giants," accounting for 90.07% of the total, with 152 being national-level little giants [2][33] - The report identifies key industry chains within the BSE, including smart connected new energy vehicles, hydrogen energy, new materials, innovative pharmaceuticals, and artificial intelligence [2][38] Group 2 - The BSE's market performance shows a decline in the North BSE 50 index, which reported 1,514.20 points, with a TTM PE ratio of 71.80X, while the specialized and innovative index reported 2,500.55 points with a TTM PE of 80.59X [3][62][66] - The average market capitalization of BSE companies is lower than that of the ChiNext and STAR Market, with the average market cap at 31.94 million yuan compared to 126.11 million yuan and 175.43 million yuan respectively [22][23] - The report notes that the liquidity of the BSE has improved, with the turnover rate now higher than that of the STAR Market and slightly above the ChiNext [41][42][47] Group 3 - The report indicates that the IPO review process is active, with two companies approved and three pending approval, reflecting a steady increase in the number of companies entering the market [3][28] - The report emphasizes the growing interest from public funds in the BSE, with 39 public institutions investing in BSE stocks by mid-2025, marking a significant increase in both the number of institutions and the amount invested [45][46] - The BSE is expected to enhance its index system and introduce the North BSE 50 ETF, which could further improve liquidity and attract more institutional investors [50][51]

上述评选的申报范围聚焦在2020年1月1日及以后在中国制造的，取得国内医疗器械注册证的产品。截至 9月末，该评选在信息征集阶段共收到来自88家企业、200项产品申报；经多轮评审，专家组共遴选出96 项推荐产品、59项提名产品。 记者注意到，从评选结果及名单来看，医疗设备类中，不乏一些国内头部厂家的先进成像设备，如迈瑞 医疗电子的光声成像超声诊断系统、东软医疗的X射线计算机体层摄影设备（光子计数CT）NeuVizP10 等。医用耗材类中，不乏一些新兴厂家的高值产品，如无锡帕母医疗的一次性使用环形肺动脉射频消融 导管、杭州糖吉医疗科技的胃转流支架系统等。 曹少平称，现阶段，医疗器械正在从"辅助工具"演进成"决策伙伴"，以及从"通用型产品"转向"个性化 服务"。比如，在诊断治疗端，一些能够实现科学、精准定量方法的影像诊断设备，更加受到临床医生 的欢迎。再比如，一些可以进行自适应操作的手术机器人、能够自动生成个性化治疗方案的工具等，也 在更多手术室内落地。此外，也有一些可进行连续监测的穿戴设备能帮助实现患者的居家健康管理。 搭载了AI技术的诊断、监测设备正在逐步成为医疗机构选择和采购的首选。 随着近年来大数据、AI（ ...

Core Viewpoint - Recently, Qufu Huizhong Medical Equipment Co., Ltd. was established with a registered capital of 50,000 RMB, indicating a new player in the medical equipment and healthcare sector [1] Company Overview - The legal representative of the company is Fang Shiyu, suggesting a potential leadership structure [1] - The company has a diverse business scope, including the sale of first-class and second-class medical devices, health products, and various consumer goods [1] Business Scope - The company is involved in the sale of general medical devices, hygiene products, disposable medical supplies, adult products (excluding drugs and medical devices), daily necessities, and pre-packaged food [1] - It also engages in internet sales of food and other products, as well as research and development of bio-based materials [1] - The company is permitted to conduct medical device internet information services, drug retail, and food sales, subject to regulatory approval [1]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [29]. Core Insights - The pharmaceutical sector saw a weekly increase of 3.3%, outperforming the Shanghai Composite Index, which decreased by 0.2% during the same period [4][6]. - The overall valuation of the pharmaceutical sector is at 30.9 times earnings, ranking it 10th among 31 primary sectors [6][12]. - Key segments within the pharmaceutical industry showed varied performance, with raw materials up by 5.1%, chemical preparations by 4.4%, and traditional Chinese medicine by 4.1% [6][4]. Market Performance - The pharmaceutical index ranked 5th among 31 sub-industries, with notable increases in various segments such as biopharmaceuticals (+2.7%), medical services (+1.8%), and medical devices (+1.8%) [4][6]. - The report highlights the performance of specific companies, recommending a focus on innovative drug sectors and companies with strong earnings growth potential [3][21]. Recent Developments - Roche's BTK inhibitor Fenebrutinib achieved significant milestones in clinical trials for treating relapsing multiple sclerosis, suggesting potential investment opportunities in related companies [3][13]. - The Chinese government has updated regulations on the export of controlled chemicals, impacting companies involved in this sector [3][14]. - The report notes an expected peak in influenza activity in China during late December and early January, prompting recommendations to monitor related vaccine and treatment companies [3][15][16]. Key Company Valuations - The report provides a valuation table for key companies in the pharmaceutical sector, indicating projected earnings per share (EPS) and price-to-earnings (PE) ratios for 2025 and beyond [21]. - Companies highlighted include Mindray Medical, Hengrui Medicine, and WuXi AppTec, with varying market capitalizations and growth forecasts [21]. Investment Recommendations - The report suggests focusing on innovative drug sectors and companies with improving performance in medical devices and upstream segments, listing specific companies to watch [3][21]. - It emphasizes the importance of monitoring flu vaccine manufacturers and antiviral drug producers as flu activity rises [3][15].

中国航天科技（000901）集团有限公司首次以"航天科技成果转化与产业化"为主题参展高交会，集中展 示了百余项航天前沿科技成果，全面展现航天技术在商业航天、低空经济、机器人、电子信息、新能源 等领域的"航天方案"与实践成果。 这是11月14日拍摄的第二十七届中国国际高新技术成果交易会现场。新华社发 深圳商报首席记者 陈小慧 亚太6D卫星、 柔性太阳翼、"深海一号"能源站、昇腾384超节点……从"上天入海"，到AI大模型技术。 第二十七届高交会9号馆里，都是备受关注的国之重器、科技巨头产业链展区。 本届高交会重点遴选"高、精、尖"技术与产品，实物展品比例超90%，举办首发首秀和路演推介活动百 余场，首发、首展展品占比达20%以上。 一馆尽览"上天入海" 据了解，整个9号馆是备受关注的国之重器、科技巨头产业链展区。一大批对国家安全和科技创新具有 重大意义的技术与产品藏身其中，涵盖航空航天、高端船舶与海洋工程装备、重大科学仪器设备、能源 装备制造、智能制造、大型工程装备等。展区内集结了中国航天、中国石化、中国海油（600938）、比 亚迪（002594）、荣耀、品胜、鸿蒙智行、中国科学院深圳先进院、光明实验室、深圳 ...